CoChat

Lorcaserin improves glycemic control via a melanocortin neurocircuit

Open access
Burke, Luke K., Ogunnowo-Bada, Emmanuel, Georgescu, Teodora, Cristiano, Claudia, de Morentin, Pablo B. Martinez, Valencia Torres, Lourdes, D'Agostino, Giuseppe, Riches, Christine, Heeley, Nicholas, Ruan, Yue, Rubinstein, Marcelo, Low, Malcolm J., Myers, Martin G., Rochford, Justin J., Evans, Mark L., Heisler, Lora K. · 2017 · Molecular Metabolism
Cited by 61

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The increasing prevalence of type 2 diabetes (T2D) and associated morbidity and mortality emphasizes the need for a more complete understanding of the mechanisms mediating glucose homeostasis to accelerate the identification of new medications. Recent reports indicate that the obesity medication lorcaserin, a 5-hydroxytryptamine (5-HT, serotonin) 2C receptor (5-HT2CR) agonist, improves glycemic control in association with weight loss in obese patients with T2D. Here we evaluate whether lorcaserin has an effect on glycemia without body weight loss and how this effect is achieved. Murine models of common and genetic T2D were utilized to probe the direct effect of lorcaserin on glycemic control. Lorcaserin dose-dependently improves glycemic control in mouse models of T2D in the absence of reductions in food intake or body weight. Examining the mechanism of this effect, we reveal a necessary and sufficient neurochemical mediator of lorcaserin's glucoregulatory effects, brain pro-opiomelanocortin (POMC) peptides. To clarify further lorcaserin's therapeutic brain circuit, we examined the receptor target of POMC peptides. We demonstrate that lorcaserin requires functional melanocortin4 receptors on cholinergic preganglionic neurons (MC4RChAT) to exert its effects on glucose homeostasis. In contrast, MC4RChAT signaling did not impact lorcaserin's effects on feeding, indicating a divergence in the neurocircuitry underpinning lorcaserin's therapeutic glycemic and anorectic effects. Hyperinsulinemic-euglycemic clamp studies reveal that lorcaserin reduces hepatic glucose production, increases glucose disposal and improves insulin sensitivity. These data suggest that lorcaserin's action within the brain represents a mechanistically novel treatment for T2D: findings of significance to a prevalent global disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmet.2017.07.004

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 61

Metadata

Authors
Burke, L. K., Ogunnowo-Bada, E., Georgescu, T., Cristiano, C., de Morentin, P. B. M., Valencia Torres, L., D'Agostino, G., Riches, C., Heeley, N., Ruan, Y., Rubinstein, M., Low, M. J., Myers, M. G., Rochford, J. J., Evans, M. L., & Heisler, L. K.
Venue
Molecular Metabolism
Publisher
Elsevier BV
Published
2017-10
Volume
6
Issue
10
Pages
1092-1102
ISSN
2212-8778 (ISSN-L)
OpenAlex
W2737160318
Cited by
61
References
11
FWCI
2.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lorcaserin improves glycemic control via a melanocortin neurocircuit. https://app.cochat.ai/papers/10.1016/j.molmet.2017.07.004
The paper
Burke, L. K., Ogunnowo-Bada, E., Georgescu, T., Cristiano, C., de Morentin, P. B. M., Valencia Torres, L., D'Agostino, G., Riches, C., Heeley, N., Ruan, Y., Rubinstein, M., Low, M. J., Myers, M. G., Rochford, J. J., Evans, M. L., & Heisler, L. K. (2017). Lorcaserin improves glycemic control via a melanocortin neurocircuit. Molecular Metabolism. https://doi.org/10.1016/j.molmet.2017.07.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.